Floatz logo

Epirubicin

ROS1 Gene Rearrangement

Dr Joanne CHIUPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the ROS1 Gene Rearrangement cohort.

Asset / SponsorPhaseRating
Crizotinib
University Health Network, Toronto
Phase 2B
Cyclophosphamide
Dr Joanne CHIU
Phase 2CCC
LENVATINIB
Dr Joanne CHIU
Phase 2CCC
Carboplatin
Dr Joanne CHIU
Phase 2CCC
Ensartinib
Betta Pharmaceuticals Co., Ltd.
Phase 2CCC

View all 13 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →